Novavax | NVAX - Gewinn Vor Steuern





Gewinn Vor Steuern Veränderung Datum
Adma Biologics USD 61.59M 14.07M 2025-12
Agenus USD -10.61M 263.52M 2025-12
AstraZeneca USD 3.24B 117M 2025-09
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Cassava Sciences USD -10.81M 33.41M 2025-09
Geron USD -31.14M 12.72M 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
MannKind USD -20.93M 28.71M 2025-12
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -187M 631M 2025-09
Novartis USD 5.17B 637M 2025-09
Novavax USD 17.9M 220.94M 2025-12
Pfizer USD 3.33B 290M 2025-09
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
TG Therapeutics USD 45.09M 19.18M 2025-12